Your browser doesn't support javascript.
loading
Omicron infection of vaccinated individuals enhances neutralizing immunity against the Delta variant.
Khan, Khadija; Karim, Farina; Cele, Sandile; San, James Emmanuel; Lustig, Gila; Tegally, Houriiyah; Rosenberg, Yuval; Bernstein, Mallory; Ganga, Yashica; Jule, Zesuliwe; Reedoy, Kajal; Ngcobo, Nokuthula; Mazibuko, Matilda; Mthabela, Ntombifuthi; Mhlane, Zoey; Mbatha, Nikiwe; Miya, Yoliswa; Giandhari, Jennifer; Ramphal, Yajna; Naidoo, Taryn; Manickchund, Nithendra; Magula, Nombulelo; Abdool Karim, Salim S; Gray, Glenda; Hanekom, Willem; von Gottberg, Anne; Milo, Ron; Gosnell, Bernadett I; Lessells, Richard J; Moore, Penny L; de Oliveira, Tulio; Moosa, Mahomed-Yunus S; Sigal, Alex.
Affiliation
  • Khan K; Africa Health Research Institute, Durban, South Africa.
  • Karim F; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Cele S; Africa Health Research Institute, Durban, South Africa.
  • San JE; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Lustig G; Africa Health Research Institute, Durban, South Africa.
  • Tegally H; School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
  • Rosenberg Y; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Bernstein M; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa.
  • Ganga Y; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Jule Z; Centre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa.
  • Reedoy K; Department of Plant and Environmental Sciences, Weizmann Institute of Science, Rehovot, Israel.
  • Ngcobo N; Africa Health Research Institute, Durban, South Africa.
  • Mazibuko M; Africa Health Research Institute, Durban, South Africa.
  • Mthabela N; Africa Health Research Institute, Durban, South Africa.
  • Mhlane Z; Africa Health Research Institute, Durban, South Africa.
  • Mbatha N; Africa Health Research Institute, Durban, South Africa.
  • Miya Y; Africa Health Research Institute, Durban, South Africa.
  • Giandhari J; Africa Health Research Institute, Durban, South Africa.
  • Ramphal Y; Africa Health Research Institute, Durban, South Africa.
  • Naidoo T; Africa Health Research Institute, Durban, South Africa.
  • Manickchund N; Africa Health Research Institute, Durban, South Africa.
  • Magula N; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Abdool Karim SS; KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa.
  • Gray G; Africa Health Research Institute, Durban, South Africa.
  • Hanekom W; Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa.
  • von Gottberg A; Department of Internal Medicine, Nelson R. Mandela School of Medicine. University of Kwa-Zulu Natal.
  • Milo R; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, United States.
  • Gosnell BI; South African Medical Research Council, Cape Town, South Africa.
  • Lessells RJ; Africa Health Research Institute, Durban, South Africa.
  • Moore PL; Division of Infection and Immunity, University College London, London, UK.
  • de Oliveira T; National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa.
  • Moosa MS; SAMRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
medRxiv ; 2022 Jan 28.
Article in En | MEDLINE | ID: mdl-34981076
ABSTRACT
Omicron variant (B.1.1.529) infections are rapidly expanding worldwide, often in settings where the Delta variant (B.1.617.2) was dominant. We investigated whether neutralizing immunity elicited by Omicron infection would also neutralize the Delta variant and the role of prior vaccination. We enrolled 23 South African participants infected with Omicron a median of 5 days post-symptoms onset (study baseline) with a last follow-up sample taken a median of 23 days post-symptoms onset. Ten participants were breakthrough cases vaccinated with Pfizer BNT162b2 or Johnson and Johnson Ad26.CoV2.S. In vaccinated participants, neutralization of Omicron increased from a geometric mean titer (GMT) FRNT50 of 28 to 378 (13.7-fold). Unvaccinated participants had similar Omicron neutralization at baseline but increased from 26 to only 113 (4.4-fold) at follow-up. Delta virus neutralization increased from 129 to 790, (6.1-fold) in vaccinated but only 18 to 46 (2.5-fold, not statistically significant) in unvaccinated participants. Therefore, in Omicron infected vaccinated individuals, Delta neutralization was 2.1-fold higher at follow-up relative to Omicron. In a separate group previously infected with Delta, neutralization of Delta was 22.5-fold higher than Omicron. Based on relative neutralization levels, Omicron re-infection would be expected to be more likely than Delta in Delta infected individuals, and in Omicron infected individuals who are vaccinated. This may give Omicron an advantage over Delta which may lead to decreasing Delta infections in regions with high infection frequencies and high vaccine coverage.

Full text: 1 Database: MEDLINE Language: En Journal: MedRxiv Year: 2022 Type: Article Affiliation country: South Africa

Full text: 1 Database: MEDLINE Language: En Journal: MedRxiv Year: 2022 Type: Article Affiliation country: South Africa